Blueprint
UNITED
STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2016.
Commission File Number: 000-53805
Intellipharmaceutics International
Inc.
(Translation of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ x
] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if
submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules
of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is
not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form
6-K submission or other Commission filing on
EDGAR.
This
Report of Foreign Private Issuer on Form 6-K and the attached
exhibits 99.1 and 99.2 shall be incorporated by reference into the
Company’s effective Registration Statements on Form F-3, as
amended and supplemented (Registration Statement Nos. 333-172796
and 333-196112), filed with the Securities and Exchange Commission,
from the date on which this Report is filed, to the extent not
superseded by documents or reports subsequently filed or furnished
by Intellipharmaceutics International Inc. under the Securities Act
of 1933 or the Securities Exchange Act of 1934.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly
authorized.
|
|
|
Intellipharmaceutics
International Inc.
|
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Domenic Della Penna
|
|
|
Date:
October 13, 2016
|
|
Domenic
Della Penna
|
|
|
|
|
Chief Financial Officer
|
|
EXHIBIT LIST
|
Exhibit
|
Description
|
|
99.1
|
Management Discussion And Analysis Of Financial Condition And
Results Of Operations for the Three and Nine Months Ended August
31, 2016
|
|
99.2
|
Condensed Unaudited Interim Consolidated Financial Statements and
Notes to Condensed Unaudited Interim Consolidated Financial
Statements of Intellipharmaceutics International Inc. for the Three
and Nine Months Ended August 31, 2016
|
|
99.3
|
News Release dated October 13, 2016 - Intellipharmaceutics
Announces Third Quarter 2016 Results
|
|
99.4
|
Form 52-109F2 - Chief Executive Officer
|
|
99.5
|
Form 52-109F2 - Chief Financial Officer
|
|
|
|